Hepatitis B virus (HBV) infection continues to be a leading cause of chronic liver disease The measurement of HBV DNA in serum can not only help monitor treatment efficacy but also indicates infection rate and drug resistance emerge. Current study includes the HBV DNA quantification in 20 positive HBsAg cases. 14 cases were undergoing antiviral treatment that was processed for HBV DNA viral load. These patients carried HBV DNA titer in between 6.00 x 100to 1.75 x 103. Out of 20 patients, 4 came negative in which target was not detected which signifies their complete remedial procedure and patients were under antiviral treatment. Advances in the molecular diagnosis of viral diseases using highly sensitive methodologies such as DNA Amplification by PCR can further detect upcoming viral resistance at an early stage when the variant represents only a minor fraction of the total viral population. Such new tools are especially relevant for patients at high risk for disease progression or acute exacerbation.